Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Lyme Disease
Mpox (Monkey Pox)
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-4800
TNX-801
TNX-4200 CD45
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
March 2026
World Vaccine Conference 2026 — A Long-Acting Monoclonal Antibody for Prevention of Lyme Disease
Mark S. Klempner, MD, UMass Chan Medical School
March 2026
8th International Congress on Controversies in Fibromyalgia Oral Presentations
Phase 3 RESILIENT Study Post Hoc Analysis
Phase 3 RELIEF and RESILIENT Pooled Post Hoc Analysis
March 2026
2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting
January 2026
Non-Opioid Pain Therapeutics Summit, Boston MA / 27-29 Jan 2026
October 2025
American College of Rheumatology Convergence Conference 2025, Chicago: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia
October 2025
World Vaccine Conference 2025, Amsterdam: Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine
October 2025
61st Annual Congress of the Japan Society for Transplantation
September 2025
PainWeek 2025 — Randomized, double-blind, placebo-controlled confirmatory Phase 3 trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in fibromyalgia
September 2025
PainWeek 2025 — Sublingual cyclobenzaprine (TNX-102 SL) for fibromyalgia: efficacy and safety in two randomized placebo-controlled trials
September 2025
PainWeek 2025 — TNX-102 SL, cyclobenzaprine HCl sublingual tablets, demonstrates pain reduction and favorable tolerability in patients with fibromyalgia
Posts navigation
Older posts